Piperacillin-induced immune hemolytic anemia in an adult with cystic fibrosis
- PMID: 20589083
- PMCID: PMC2892651
- DOI: 10.1155/2010/161454
Piperacillin-induced immune hemolytic anemia in an adult with cystic fibrosis
Abstract
We report a case of drug-induced immune hemolytic anemia (DIIHA) in an adult female with cystic fibrosis (CF), complicating routine treatment of a pulmonary exacerbation with intravenous piperacillin-tazobactam. Workup revealed a positive direct antiglobulin test (DAT) due to red blood cell (RBC)-bound IgG and C3 and piperacillin antibodies detectable in the patient's serum. The potential influence of CF transmembrane conductance regulator mutations on the severity of DIIHA is discussed. This report illustrates the importance of early identification of DIIHA, a rare complication of a commonly utilized medication in CF.
Figures
References
-
- Johnson C, Butler SM, Konstan MW, Morgan W, Wohl MEB. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest. 2003;123(1):20–27. - PubMed
-
- Seder DB, Zuckerman JB. Piperacillin-indued immune hemolytic anemia in a woman with cystic fibrosis. Chest. 2006;130(4):p. 325S.
-
- Arndt PA, Garratty G, Hill J, Kasper M, Chandrasekaran V. Two cases of immune haemolytic anaemia, associated with anti-piperacillin, detected by the ‘immune complex’ method. Vox Sanguinis. 2002;83(3):273–278. - PubMed
-
- Leger RM, Arndt PA, Garratty G. Serological studies of piperacillin antibodies. Transfusion. 2008;48(11):2429–2434. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous